Biologic Treatment for Hidradenitis Suppurativa.
Flood, Kelsey S, Martina L Porter, and Alexa B Kimball. 2019. “Biologic Treatment for Hidradenitis Suppurativa.”. American Journal of Clinical Dermatology 20 (5): 625-38.
Search
Search results
399 results found
Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.
Kimball, A B, A Ganguli, and A Fleischer. 2018. “Reliability of the Hidradenitis Suppurativa Clinical Response in the Assessment of Patients With Hidradenitis Suppurativa.”. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (12): 2254-56.
Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials.
Kimball, Alexandra B, Murali Sundaram, Alan L Shields, Stacie Hudgens, Martin Okun, Catherine Foley, and Arijit Ganguli. 2018. “Adalimumab Alleviates Skin Pain in Patients With Moderate-to-Severe Hidradenitis Suppurativa: Secondary Efficacy Results from the PIONEER I and PIONEER II Randomized Controlled Trials.”. Journal of the American Academy of Dermatology 79 (6): 1141-43.
Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
Porter, Martina L, Nicole M Golbari, Stephen J Lockwood, and Alexa B Kimball. 2018. “Overview and Update on Biologic Therapy for Moderate-to-Severe Hidradenitis Suppurativa.”. Seminars in Cutaneous Medicine and Surgery 37 (3): 182-89.
Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson, C C, and A B Kimball. 2004. “Rethinking the Psoriasis Area and Severity Index: The Impact of Area Should Be Increased.”. The British Journal of Dermatology 151 (2): 381-7.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
Papp, Kim A, Bruce Strober, Matthias Augustin, Steve Calabro, Anil Londhe, Marc Chevrier, and PSOLAR investigators and Steering Committee. 2012. “PSOLAR: Design, Utility, and Preliminary Results of a Prospective, International, Disease-Based Registry of Patients With Psoriasis Who Are Receiving, or Are Candidates For, Conventional Systemic Treatments or Biologic Agents.”. Journal of Drugs in Dermatology : JDD 11 (10): 1210-7.
Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
Alora-Palli, Maria B, Alexis C Perkins, Alicia Van Cott, and Alexandra B Kimball. 2010. “Efficacy and Tolerability of a Cosmetically Acceptable Coal Tar Solution in the Treatment of Moderate Plaque Psoriasis: A Controlled Comparison With Calcipotriene (calcipotriol) Cream.”. American Journal of Clinical Dermatology 11 (4): 275-83.
Future perspectives/quo vadis psoriasis treatment? Immunology, pharmacogenomics, and epidemiology.
Kimball, Alexa B, and Thomas S Kupper. 2008. “Future Perspectives/Quo Vadis Psoriasis Treatment? Immunology, Pharmacogenomics, and Epidemiology.”. Clinics in Dermatology 26 (5): 554-61.
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Menter, Alan, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, et al. 2008. “Adalimumab Therapy for Moderate to Severe Psoriasis: A Randomized, Controlled Phase III Trial.”. Journal of the American Academy of Dermatology 58 (1): 106-15.
An assessment of the cost-utility of therapy for psoriasis.
Weiss, Stefan C, Wingfield Rehmus, and Alexa B Kimball. 2006. “An Assessment of the Cost-Utility of Therapy for Psoriasis.”. Therapeutics and Clinical Risk Management 2 (3): 325-8.